Switchpoint Bio
Switchpoint Bio combines epigenomics and AI to decode DNA methylation marks in circulating immune cells from a single blood draw, turning cellular biology into decision-grade evidence for drug development. The platform supports disease biology discovery, patient stratification for trial enrichment, and treatment response monitoring for pharmaceutical and clinical research applications.
- Biotechnology
- Drug Discovery & Therapeutics
- Data & Analytics
- Healthcare Technology
- Artificial Intelligence
- Software Only
Funding
Founders
Founder details are not available yet.
Product
Problem
Drug development and clinical research often lack precise, biology-based tools to define disease states, stratify patients, and track treatment effects. Standard genomic approaches miss the regulatory layer of cellular biology, and blood-based biomarkers rarely capture the dynamic immune cell states that underlie disease progression and therapeutic response.
Solution
Switchpoint Bio brings together epigenomics and AI to turn cellular biology into decision-grade evidence for drug development and clinical research. The platform reads DNA methylation marks in circulating immune cells, which act as a systemic sensor carrying a molecular record of the whole body in every blood draw. Using one assay, the company reveals which immune cells are present, their regulatory states, and how those states change with disease and treatment. Proprietary AI models interpret these epigenetic signatures to define disease biology, identify biomarkers, and generate insights into patient stratification and trial enrichment.
Target Audience
Primary customers are pharmaceutical companies and clinical research organizations conducting drug development programs, especially in immunology, oncology, and other therapy areas where immune cell states and treatment response biomarkers are critical.
Features
- Blood-based DNA methylation assay that captures immune cell composition and regulatory states from a single sample
- AI-powered analytics that decode epigenetic signatures into interpretable biomarkers for disease states and cellular mechanisms
- Disease biology and biomarker discovery capabilities that reveal known and novel disease states
- Patient stratification tools that identify biologically defined patient groups to enrich clinical trials and sharpen readouts
- Treatment response monitoring that tracks cellular state changes during therapy to reveal response, resistance, and mechanism of action
- Platform designed to operate at scale for pharmaceutical and clinical research applications